Literature DB >> 17055353

Regulatory T cells and transplantation tolerance.

Shuiping Jiang1, Robert I Lechler, Xiao-Shun He, Jie-Fu Huang.   

Abstract

In the past decade, several types of regulatory T cells (Tregs) have been identified to play a pivotal role in the control of autoimmunity and transplantation tolerance in rodents and in human beings, including innate regulatory NKT cells and gammadelta T cells, naturally occurring FoxP3 expressing CD4(+)CD25(+) T cells, and in-vitro induced Tregs including interleuking-10 (IL-10)-secreting Tr1 CD4(+) T cells, TGF-beta-producing Th3 CD4(+) T cells, anergic CD4(+) T cells, CD8(+)CD28(-) and CD3(+)CD4(-)CD8(-) T cells. Recent studies have shown that innate and adaptive Tregs may be linked and act in concert to mediate immunosuppression. As our understanding of regulatory T cell populations has substantially advanced, compelling evidence support the prospect that in-vitro expanded, patient-tailored Tregs with indirect anti-donor allospecificity could be potential reagents as adoptive cell therapy for individualized medicine to promote clinical transplantation tolerance.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17055353     DOI: 10.1016/j.humimm.2006.07.013

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  27 in total

1.  IL-10 enhances promoter activity of ILT4 gene and up-regulates its expression in THP-1 cells.

Authors:  Xiaoli Xu; Ping Zou; Lijuan Chen; Guannan Jin; Hao Zhou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

2.  Indoleamine 2,3-dioxygenase and regulatory dendritic cells contribute to the allograft protection induced by infusion of donor-specific splenic stromal cells.

Authors:  Li Liu; Lihua Duan; Min Gong; Hong Dai; Quan Gong; Fang Zheng; Zheng Tan; Congyi Wang; Feili Gong; Min Fang
Journal:  Cell Mol Immunol       Date:  2010-11-08       Impact factor: 11.530

Review 3.  Regulatory T cells in lung transplantation--an emerging concept.

Authors:  David C Neujahr; Christian P Larsen
Journal:  Semin Immunopathol       Date:  2011-03-20       Impact factor: 9.623

Review 4.  New and emerging therapies for acute and chronic graft versus host disease.

Authors:  LaQuisa Hill; Amin Alousi; Partow Kebriaei; Rohtesh Mehta; Katayoun Rezvani; Elizabeth Shpall
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 5.  [Typing for HLA matching. Advantages for keratoplasty].

Authors:  R Ignatius; F Hoffmann
Journal:  Ophthalmologe       Date:  2007-03       Impact factor: 1.059

6.  T regulatory cell mediated immunotherapy for solid organ transplantation: A clinical perspective.

Authors:  Mohammad Afzal Khan
Journal:  Mol Med       Date:  2016-11-22       Impact factor: 6.354

7.  The synergistic effect of Tautomycetin on Cyclosporine A-mediated immunosuppression in a rodent islet allograft model.

Authors:  Yu-Mee Wee; Monica Young Choi; Choong-Hoon Kang; Yang-Hee Kim; Jin-Hee Kim; Sang-Kyou Lee; Seung-Young Yu; Song-Cheol Kim; Duck-Jong Han
Journal:  Mol Med       Date:  2010-04-30       Impact factor: 6.354

8.  Regulatory T cells in renal disease.

Authors:  Yuan Min Wang; Min Hu; Ya Wang; Tania Polhill; Geoff Yu Zhang; Yiping Wang; Vincent W S Lee; David C H Harris; Stephen I Alexander
Journal:  Int J Clin Exp Med       Date:  2008-08-20

9.  Resveratrol (trans-3,5,4'-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor.

Authors:  Narendra P Singh; Venkatesh L Hegde; Lorne J Hofseth; Mitzi Nagarkatti; Prakash Nagarkatti
Journal:  Mol Pharmacol       Date:  2007-09-14       Impact factor: 4.436

10.  In situ activation and expansion of host tregs: a new approach to enhance donor chimerism and stable engraftment in major histocompatibility complex-matched allogeneic hematopoietic cell transplantation.

Authors:  Alwi Shatry; Robert B Levy
Journal:  Biol Blood Marrow Transplant       Date:  2009-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.